Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 Jan;96(1):5-8.
doi: 10.3324/haematol.2010.034397.

In search of the optimal iron chelation therapy for patients with thalassemia major

Vasilios Berdoukas, John Wood
Editorial

In search of the optimal iron chelation therapy for patients with thalassemia major

Vasilios Berdoukas et al. Haematologica. 2011 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier curve showing the proportion of patients who developed overt cardiac failure over a 12-month period according to their baseline cardiac T2* value if no changes were made to their chelation regime. Reproduced with permission from Kirk P et al.
Figure 2.
Figure 2.
Cardiac magnetic resonance imaging T2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. (A) Scatter diagram and regression line of the 5-year ferritin compared to the Cardiac T2*. The vertical red dotted line indicates the T2* value below which cardiac iron is considered to be present. The horizontal green dotted line represents the mean ferritin value above which a patient is considered to be at risk of cardiac problems. (B) Scatter diagram of hepatic T2* compared to cardiac T2*. The three horizontal dotted lines indicate the divisions of hepatic T2* that are associated with acceptable (>5.2), (green) mild (2.5–5.2), (yellow) moderate (1–2.5 ms) and (fine dotted red) heavy (<1ms). The vertical red dotted line indicates the level of cardiac T2* that differentiates between a normal and an iron-loaded heart. Adapted from Aessopos et al.
See this image and copyright information in PMC

Comment on

References

    1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–93. - PubMed
    1. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica. 2006;91(9):1187–92. - PubMed
    1. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10(1):42. - PMC - PubMed
    1. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann NY Acad Sci. 2005;1054:445–50. - PubMed
    1. Telfer P. Update on survival in thalassemia major. Hemoglobin. 2009;33 (Suppl 1):S76–80. - PubMed

MeSH terms

Substances